Phase III ARIEL4 study of Rubraca meets primary endpoint in relapsed ovarian cancer.- Clovis Oncology
Related news and insights
On Target Laboratories, Inc., a privately-held biotechnology company developing fluorescent imaging agents to target and illuminate cancer during surgery, announced that the FDA has approved Cytalux for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.
ImmunoGen announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of IMGN 853 (mirvetuximab soravtansine monotherapy in patients with folate receptor alpha (FR?)-high platinum-resistant ovarian cancer who have been previously treated with Avastin (bevacizumab).
Alkermes plc announced the initiation of ARTISTRY-7, a global phase III open-label, randomized trial evaluating the anti-tumor activity and safety of intravenously administered (IV) nemvaleukin alfa (nemvaleukin), in combination with pembrolizumab, compared to investigator's choice chemotherapy, in patients with platinum-resistant ovarian cancer.